Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;20(30):2293-2302.
doi: 10.1080/14796694.2024.2386929. Epub 2024 Sep 5.

Cancer immunotherapy of Wilms tumor: a narrative review

Yu Lin He  1   2 , Jin Yan Liu  2 , Rahma Taher Almgrami  2 , Ying Zhong Fan  1 , Yi Zhang  2
Affiliations
Review

Cancer immunotherapy of Wilms tumor: a narrative review

Yu Lin He et al. Future Oncol. 2024.

Abstract

Wilms tumor (WT) is the most common malignant tumor of the urinary system in children. Though the traditional treatment of surgery plus radiotherapy and chemotherapy achieves exciting clinical efficacy, in relapsed and refractory cases, the long-term overall survival rates are poor. Besides, chemotherapy and radiation have serious long-term toxic side effects on children. Cancer immunotherapy is a new tumor therapy that works by activating the body's immune system to allow immune cells to kill tumor cells more efficiently. Currently, cancer immunotherapy has been tested in clinical trials or basic studies in WT. This article reviews the current status of clinical trials and basic research of cancer immunotherapy in WT to promote the application of cancer immunotherapy in WT patients.

Keywords: Wilms tumor; cancer immunotherapy; immune cell therapy; immune checkpoint; therapeutic tumor vaccine.

Plain language summary

[Box: see text].

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Similar articles

See all similar articles

Cited by

References

    1. Palmisani F, Kovar H, Kager L, et al. . Systematic review of the immunological landscape of Wilms tumors. Mol Ther Oncolytics. 2021;22:454–467. doi:10.1016/j.omto.2021.06.016 - DOI - PMC - PubMed
    1. Stokes CL, Stokes WA, Kalapurakal JA, et al. . Timing of radiation therapy in pediatric Wilms tumor: a report from the national cancer database. Int J Radiat Oncol Biol Phys. 2018;101(2):453–461. doi:10.1016/j.ijrobp.2018.01.110 - DOI - PubMed
    1. Malogolowkin M, Cotton CA, Green DM, et al. . Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group. Pediatr Blood Cancer. 2008;50(2):236–241. doi:10.1002/pbc.21267 - DOI - PubMed
    1. Cotton CA, Peterson S, Norkool PA, et al. . Early and late mortality after diagnosis of wilms tumor. J Clin Oncol. 2009;27(8):1304–1309. doi:10.1200/JCO.2008.18.6981 - DOI - PMC - PubMed
    1. Baxevanis CN, Perez SA, Papamichail M. Cancer immunotherapy. Crit Rev Clin Lab Sci. 2009;46(4):167–189. doi:10.1080/10408360902937809 - DOI - PubMed

Substances

LinkOut - more resources